Economic and cost-effectiveness considerations for pharmacogenetics tests: An integral part of translational research and innovation uptake in personalized medicine

Current Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 4, 2009, Pages 284-296

  Paci, D ^a   Ibarreta, D ^a  

^a JOINT RESEARCH CENTRE   (Italy)

Author keywords

Cost effectiveness; Diagnostics; Economic evaluation; Pharmacogenetics; Translational research

Indexed keywords

6 METHYLTHIOINOSINE; ABACAVIR; AZATHIOPRINE; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 5 LEIDEN; CYTOCHROME P450 2C9; DRUG METABOLIZING ENZYME; EFAVIRENZ; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA B57 ANTIGEN; LAMIVUDINE; MENADIONE EPOXIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TENOFOVIR; THIOGUANOSINE; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLEEDING; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG HYPERSENSITIVITY; DRUG SURVEILLANCE PROGRAM; ECONOMIC ASPECT; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; GOVERNMENT; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUALIZATION; MEDICAL LITERATURE; MEDICAL RESEARCH; NEUTROPENIA; OUTCOME ASSESSMENT; PATENT; PATIENT CARE; PHARMACOGENETICS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE ALLOCATION; REVIEW; RISK BENEFIT ANALYSIS; SKIN DISEASE; TECHNOLOGY;

EID: 73649085130     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569209790112355     Document Type: Review

References (108)

1. Davis JC, Furstenthal L, Desai AA, et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat Rev Drug Discov 2009; 8(4): 279-86.
2. Drummond M, Sculpher M, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd Rev Ed. Oxford: Oxford University Press 2005.
3. Atun RA, Gurol-Urganci I, Sheridan D. Uptake and diffusion of pharmaceutical innovations in health systems. In: Atun RA, Sheridan D. Eds. Innovation in the biopharmaceutical industry. London: World Scientific Publishing Company 2007; pp. 85-108.
4. SACGHS (Secretary's Advisory Committee on Genetics, Health, and Society). Realizing the promise of pharmacogenomics: opportunities and phallenges 2008. [Accessed October 21, 2009]. Available from: http://oba.od.nih.gov/oba/SACGHS/ reports/SACGHS-PGx-report.pdf
5. Blumenthal D, Zeckhauser R. Genetic diagnosis: implications for medical practice. IJTAHC 1989; 5(4): 579-600.
6. The Royal Society. Personalised medicines: hopes and realities 2005. [Accessed October 21, 2009]. Available from: http://royalsociety.org/ displaypagedoc.asp?id=15874
7. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. Br Med J 2004; 329: 15-9.
8. Hitchen L. Adverse drug reactions result in 250000 UK admissions a year. Br Med J 2006; 332: 1109.
9. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-5.
10. Zika E, Gurwitz D, Ibarreta D, et al. Pharmacogenetics and pharmacogenomics: state-of-the-art and potential socio-economic impacts in the EU. EUR 22214 EN. (2006). [Accessed October 21, 2009]. Available from: http://ipts.jrc.ec.europa.eu/publications/pub.cfm?id=1387
11. Webster A, Martin P, Lewis G, et al. Integrating pharmacogenetics into society: in search of a model. Nat Rev Genet 2004; 5: 7-13.
12. Hopkins MM, Ibarreta D, Gaisser S, et al. Putting pharmacogenetics into practice. Nat Biotechnol 2006; 24: 403-10.
13. Fuks NL, Moldrup C. The diffusion of innovation: factors influencing the uptake of pharmacogenetics. Commun Genet 2007; 10: 231-41.
14. Fargher EA, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007; 32(2): 187-95.
15. Ozdemir V, Williams-Jones B, Cooper DM, et al. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 2007; 8(2): 177-85.
16. Khoury MJ, Gwinn M, Yoon PW, et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9(10): 665-74.
17. Haddow JE, Palomaki GE. ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. In: Khoury M, Little J, Burke W. Eds. Human genome epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford University Press 2003; pp. 217-33.
18. Califf RM. Defining the balance of risk and benefit in the era of genomics and proteomics. Health Aff 2004; 23(1): 77-87.
19. Omenn GS. Genomics and public health. Issues Sci Technol 2005; 21(3): 42-8.
20. UK Pharmacogenetics Study Group. Policy Issues in Pharmacogenetics: A Policy Briefing from the UK Pharmacogenetics Study Group (2006). [Accessed October 21, 2009]. Available from: http://www.york.ac.uk/res/pgx/publications/ PGxpolicyissues2006.pdf
21. Aspinall MG, Hamermesh RG. Realizing the promise of personalized medicine. Harvard Bus Rev 2007; 85(10): 108-17.
22. Rogowski W. Current impact of gene technology on healthcare: a map of economic assessments. Health Policy 2007; 80(2): 340-57.
23. Rogowski W. Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess 2006; 22(3): 327-37.
24. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 2005; 15: 365-9.
25. Kollek R, van Aken J, Feuerstein G, et al. Pharmacogenetics, adverse drug reactions and public health. Commun Genet 2006; 9: 50-4.
26. Woelderlink A, Ibarreta D, Hopkins M, et al. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J 2006; 6(1): 3-7.
27. Gurwitz D, Zika E, Hopkins MM, et al. Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics 2009; 12: 134-41.
28. Lenfant C. Shattuck lecture: clinical research to clinical practice: lost in translation? N Engl J Med 2003; 349: 868-74.
29. Brand A, Brand H, Schulte in den Baumen T. The impact of genetics and genomics on public health. Eur J Hum Genet 2008; 16(1): 5-13.
30. Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the Abacavir example. Mol Diagn Ther 2009; 13(1): 1-9.
31. Rogowski WH, Grosse SD, Khoury MJ. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 2009; 10(7): 489-95.
32. Grossman I. Routine pharmacogenetic testing in clinical practice: dream or reality? Pharmacogenomics 2007; 8: 1449-59.
33. Phillips KA, Liang SY, Van Bebber S, et al. Challenges to the translation of genomic information into clinical practice and health policy: utilization, preferences and economic value. Curr Opin Mol Ther 2008; 10(3): 260-6.
34. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 2004; 22(8): 481-93.
35. Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007; 4(8): e209.
36. Garrison LP, Carlson RJ, Carlson JJ, et al. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metab Rev 2008; 40(2): 377-401.
37. Gurwitz D, Rodriguez-Antona C, Payne K, et al. Improving pharmaco-vigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet 2009; 6(1); 103-13.
38. Deverka PA, McLeod HL. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin Pharmacol Ther 2008; 84(2): 191-3.
39. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 2004; 5: 1139-49.
40. Gold MR, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press 1996.
41. Compagni A, Bartoli S, Buehrlen B, et al. Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects. Int J Technol Assess 2008; 24(3): 294-302.
42. Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 2004; 43(2): 156-63.
43. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29(12): 2507-12.
44. van den Akker-van Marle ME, Gurwitz D, Detmar SB, et al. Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 2006; 7(5): 783-92.
45. Payne K, Newman WG, Gurwitz D, et al. TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'? Person Med 2009; 6(1): 103-13.
46. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modeling in health technology assessment: a review and consolidation of quality of assessment. Pharmacoeconomics 2006; 24: 355-71.
47. Vegter S, Boersma C, Rozenbaum M, et al. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes. A systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26(7): 569-87.
48. International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world. 2006 [Accessed October 21, 2009]. Available from: http://www.ispor.org/PEguide 29.index.asp
49. Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20(6): 593-9.
50. Priest VL, Begg EJ, Gardiner SJ, et al. Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease. Pharmacoeconomics 2006; 24(8): 767-81.
51. Tavadia SMB, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: A pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42(4): 628-32.
52. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005; 100(10): 2239-47.
53. Younossi ZM, Singer ME, McHutchison JG, et al. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30(5): 1318-24.
54. Auerbach AD, Sanders GD, Hambleton J. Cost-effectiveness of testing for hypercoagulability and effects on treatment strategies in patients with deep vein thrombosis. Am J Med 2004; 116(12): 816-28.
55. Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999; 72(4): 646-51.
56. Marchetti M, Pistorio A, Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden - cost-effectiveness analysis. Thromb Haemost 2000; 84(5): 752-7.
57. Marchetti M, Pistorio A, Barone M, et al. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001; 111(2): 130-9.
58. Elkin EB, Weinstein MC, Winer EP, et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a costeffectiveness analysis. J Clin Oncol 2004; 22(5): 854-63.
59. Weinstein MC, Goldie SJ, Losina E, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med 2001; 134(6): 440-50.
60. Eckman MH, Singh SK, Erban JK, et al. Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis. Med Decis Making 2002; 22(2): 108-24.
61. Wong PY, Coghlan PJ, Angus PW. Should we be screening blood donors for hepatitis G virus? The case against screening. Med J Aust 1998; 169(7): 375-7.
62. Prashker MJ, Meenan RF. The total cost of drug therapy for rheumatoid arthritis. A model based on cost of drug, monitoring, and toxicity. Arthritis Rheum 1995; 38: 318-25.
63. You JH, Chan FW, Wong RS, et al. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy: a decision analysis. Thromb Haemost 2004; 92(3): 590-7.
64. Schalekamp T, Boink GJ, Visser LE, et al. CYP2C9 genotyping in acenocoumarol treatment: Is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther 2006; 79: 511-20.
65. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41(12): 913-58.
66. Lehmann DF, Medicis JJ, Franklin PD. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. J Clin Pharmacol 2003; 43(12): 1316-23.
67. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007; 81(4): 521-8.
68. Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psycopharmacol 2000; 20(2): 246-51.
69. Perlis RH, Ganz DA, Avorn J, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 2005; 25(5): 427-34.
70. Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics 2006; 16(2): 139-47.
71. Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics 2004; 14(1): 53-60.
72. Costa-Scharplatz M, van Asselt AD, Bachmann LM, et al. Cost-effectiveness of pharmacogenetic testing to predict treatment response to angiotensin-converting enzyme inhibitor. Pharmacogenet Genomics 2007; 17(5): 359-68.
73. Kim SK, Jun JB, El-Sohemy A, et al. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 2006; 33(7): 1266-74.
74. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing Abacavir hypersensitivity. Pharmacogenetics 2004; 14(6): 335-42.
75. Veenstra DL, Harris J, Gibson RL, et al. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genet Med 2007; 9(10): 695-704.
76. Welton NJ, Jonstone EC, David SP, et al. A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polimorphism to aid tratment choice for smoking cessation. Nicotine Tobacco Res 2008; 10(1): 231-40.
77. Heitjan DF, Asch DA, Ray R, et al. Cost effectiveness of pharmacogetetic testing to tailor smoking cessation treatment. Pharmacogenomic J 2008; 8(6): 391-9.
78. Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008; 22(15): 2025-33.
79. Eckman MH, Rosand J, Greenberg SM, et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009; 150(2): 139-41.
80. Gold MR, Siegel JE, Russell LB, et al. eds. Cost-effectiveness in health and medicine. New York: Oxford University Press 1996; pp. 176-209.
81. Weinstein MC, Siegel JE, Gold MR, et al. The recommendations of the panel of cost-effectiveness analysis in health and medicine. JAMA 1996; 276: 1253-58.
82. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-441.
83. Boulenger S, Nixon J, Drummond M, et al. Can economic evaluations be made more transferable? Eur J Health Econom 2005; 6: 334-46.
84. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001; 4(3): 225-50.
85. Dervieux T, Bala MV. Overview of the pharmacoeconomics of pharmacogenetics. Pharmacogenomics 2006; 7(8): 1175-84.
86. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11(1): 3-14.
87. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet 2002; 360(9334): 711-5.
88. Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997; 2(1): 26-30.
89. Farahani P, Levine M. Pharmacovigilance in a genomic era. Pharmacogenomics J 2006; 6(3): 158-61.
90. Ginsburg GS, Konstance RP, Allsbrook JS, et al. Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med 2005; 165: 2331-36.
91. Brazell C, Freeman A, Mosteller M. Maximising the value of medicines by including pharmacogenetic research in drug development and surveillance. Br J Clin Pharmacol 2002; 53: 224-31.
92. Roses AD. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLAB(*) 5701 as a model of safety. Neuropsychopharmacology 2009; 34(1): 6-17.
93. Tollman P, Guy P, Altshuler J, et al. A revolution in R&D: How genomics and genetics are transforming the biopharmaceutical industry. Boston: Boston Consulting Group 2001.
94. Pirmohamed M, Lewis G. Implications of pharmacogenetics and pharmacogenomics for drug development and health care. In: Mossialos E, Mrazek M, Walley T. Eds. Regulating pharmaceuticals in Europe: Striving for efficiency, equity and quality. London: European Observatory on Health Care Systems/Open University Press 2004.
95. Martin P, Morrison M. Realising the potential of genomic medicine. Institute for the study of Genetics, Biorisks and Society. University of Nottingham 2006. [Accessed October 21, 2009]. Available from: http://www.shef.ac.uk/content/1/c6/08/15/66/ Genetics%20Final%20Report%20as%20published.pdf
96. Martin P, Lewis G, Smart A, et al. False positive? The clinical and commercial development of pharmacogenetics. 2006. [Accessed October 21, 2009]. Available from: http://www.york.ac.uk/res/pgx/publications/ FalsePositive2006.pdf
97. Bates BR, Poirot K, Harris TM, et al. Evaluating direct-to-consumer marketing of race-based pharmacogenomics: a focus group study of public understandings of applied genomic medication. J Health Commum 2004; 9(6): 541-59.
98. Brand AM, Probst-Hensch NM. Biobanking for epidemiological research and public health. Pathobiology 2007; 74(4): 227-38.
99. Omenn GS. Genomics and public health. Issues in Science and Technology 2005; 21(3): 42-8.
100. nd ed. New York: Oxford University Press 2006.
101. Paci D, Schweitzer SO. Technology policy and social policy: how industrial policy applies to health. In: Bianchi P, Labory S. Eds. International Handbook of Industrial Policy. Cheltenham, UK: Edward Elgar 2006.
102. Gassmann O, Reepmeyer G, Von Zedtwitz M. Leading pharmaceutical innovation: trends and drivers for growth in the pharmaceutical industry. Heidelberg: Springer-Verlag 2004.
103. Danzon P, Towse A. The economics of gene therapy and of pharmacogenetics. Value Health 2002; 5: 5-13.
104. Garrison L, Austin FM. Linking Pharmacogenetics-based diagnostics and drugs for personalised medicine. Health Aff 2006; 25: 1281-90.
105. Phillips KA. Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA 2008; 300(21): 2542-4.
106. Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22(13): 857-76.
107. Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost effectiveness studies. Med Care 2003; 41(1): 32-44.
108. Claxton K. The irrelevance of inference: a decision making approach to the stochastic evaluation of healthcare technologies. J Health Econ 1999; 18(3): 341-64.